Related Experiment Videos
Antituberculosis drugs and new drug development
S Agrawal1, N S Thomas, A B Dhanikula
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India.
Current Opinion in Pulmonary Medicine
|May 24, 2001
Summary
New antituberculosis drugs are urgently needed to combat tuberculosis (TB), a global health emergency. This review highlights promising new chemical entities and the crucial role of biopharmaceutics and pharmacokinetics in developing effective TB treatments.
Area of Science:
- Microbiology
- Pharmacology
- Drug Development
Background:
- Tuberculosis (TB) remains a significant global health challenge, impacting millions economically, psychologically, and socially.
- Since 1993, advancements like short-course directly observed treatment and fixed-dose combinations have been implemented.
- Current TB treatment regimens face challenges including long durations, patient noncompliance, and the emergence of drug resistance.
Purpose of the Study:
- To review novel chemical entities with the potential to become new antituberculosis drugs.
- To emphasize the critical role of biopharmaceutics and pharmacokinetics in overcoming drug development hurdles.
Main Methods:
- Review of emerging chemical entities for antituberculosis activity.
- Analysis of biopharmaceutical and pharmacokinetic considerations in drug development.
Main Results:
- Identification of new chemical entities showing promise as future antituberculosis agents.
- Highlighting the importance of biopharmaceutics and pharmacokinetics in streamlining drug discovery.
Conclusions:
- New antituberculosis drugs are essential to address treatment limitations and drug resistance.
- Biopharmaceutics and pharmacokinetics are indispensable for efficient and cost-effective development of novel TB therapies.